TH167368B - Use of PAR-1 antagonists for the prevention and / or treatment of the condition. Functional pathology of the pelvic-perineal floor. - Google Patents
Use of PAR-1 antagonists for the prevention and / or treatment of the condition. Functional pathology of the pelvic-perineal floor.Info
- Publication number
- TH167368B TH167368B TH1601003560A TH1601003560A TH167368B TH 167368 B TH167368 B TH 167368B TH 1601003560 A TH1601003560 A TH 1601003560A TH 1601003560 A TH1601003560 A TH 1601003560A TH 167368 B TH167368 B TH 167368B
- Authority
- TH
- Thailand
- Prior art keywords
- prevention
- pelvic
- treatment
- antagonists
- fluoro
- Prior art date
Links
- 230000003042 antagnostic Effects 0.000 title claims abstract 9
- 239000005557 antagonist Substances 0.000 title claims abstract 9
- 101710038729 F2R Proteins 0.000 title claims abstract 8
- 101700001948 F2R Proteins 0.000 title claims abstract 8
- 230000002265 prevention Effects 0.000 title claims abstract 4
- 101700064507 MARK2 Proteins 0.000 title 1
- 102100000541 MARK2 Human genes 0.000 title 1
- 101700057002 NAPA Proteins 0.000 claims abstract 7
- 102100010801 SLC52A2 Human genes 0.000 claims abstract 7
- 101710004324 SLC52A2 Proteins 0.000 claims abstract 7
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims abstract 5
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims abstract 5
- QWKAUGRRIXBIPO-UHFFFAOYSA-N 1-(3-tert-butyl-4-methoxy-5-morpholin-4-ylphenyl)-2-(5,6-diethoxy-4-fluoro-3-imino-1H-isoindol-2-yl)ethanone Chemical compound N=C1C=2C(F)=C(OCC)C(OCC)=CC=2CN1CC(=O)C(C=C(C=1OC)C(C)(C)C)=CC=1N1CCOCC1 QWKAUGRRIXBIPO-UHFFFAOYSA-N 0.000 claims abstract 3
- 229950007648 Atopaxar Drugs 0.000 claims abstract 3
- ZBGXUVOIWDMMJE-QHNZEKIYSA-N Vorapaxar Chemical compound C(/[C@@H]1[C@H]2[C@H](C(O[C@@H]2C)=O)C[C@H]2[C@H]1CC[C@H](C2)NC(=O)OCC)=C\C(N=C1)=CC=C1C1=CC=CC(F)=C1 ZBGXUVOIWDMMJE-QHNZEKIYSA-N 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 239000011780 sodium chloride Substances 0.000 claims abstract 3
- 229960005044 vorapaxar Drugs 0.000 claims abstract 3
- 229940079593 drugs Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 206010011796 Cystitis interstitial Diseases 0.000 abstract 2
- 230000001575 pathological Effects 0.000 abstract 2
- 210000003903 Pelvic Floor Anatomy 0.000 abstract 1
Abstract
แก้ไข 08/09/2559 การประดิษฐ์ครั้งนี้จะเกี่ยวข้องกับการใช้งานของ PAR1 แอนทาโกนิสต์ (PAR1 antagonists), โดยเฉพาะอย่างยิ่ง ของวอราพาซาร์ (vorapaxar), ชนิดอะโตพาซาร์ (atopaxar) และของ 3-(2-คลอโร-ฟีนิล)-1-[4-(4-ฟลูออโร-เบนซิล)-ไพเพอราซิน-1-อิล]-โพรเพโนน (3-(2-Chloro- phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone), หรือเกลือที่ยอมรับได้เชิงเภสัชกรรม ของพวกมัน, สำหรับการป้องกันและ/หรือการบำบัดสภาวะทางพยาธิวิทยาเชิงการทำหน้าที่ของ อุ้งเชิงกราน-ฝีเย็บ, และโดยเฉพาะอย่างยิ่ง กลุ่มอาการเจ็บปวดกระเพาะปัสสาวะ ----------------------------------------------------------------------------------------------------- การประดิษฐ์ครั้งนี้จะเกี่ยวข้องกับการใช้ PAR1 แอนทาโกนิสต์ (PAR1 antagonists) โดยเฉพาะอย่างยิ่ง ชนิดวอราพาซาร์ (vorapaxar),ชนิดอะโตพาซาร์ (atopaxar) และชนิด 3-(2-คลอโร- ฟีนิล)-1-[4-(4-ฟลูออโร-เบนซิล)-ไพเพอราซิน-1-อิล]-โพรเพโนน (3-(2-chloro-phenyl)-1-[4-(4- fluoro-benzyl)-piperazn-1-yl]-propenone), หรือเกลือที่ยอมรับได้เชิงเภสัชกรรมของพวกมัน สำหรับการป้องกันและ/หรือการบำบัดสภาวะทางพยาธิวิทยาเชิงหน้าที่ของอุ้งเชิงกรานและฝีเย็บ,และ โดยเฉพาะอย่างยิ่งมากกว่า กลุ่มอาการเจ็บปวดกระเพาะปัสสาวะ EDIT 08/09/2016 This invention involves the use of PAR1 Antagonists (PAR1 antagonists), in particular. Of vorapaxar, atopaxar type and of 3- (2-chloro-phenyl) -1- (4- (4- fluoro-benzyl) - pi. Peracin-1-il) - propenone (3- (2-Chloro- phenyl) -1- (4- (4-fluoro-benzyl) -piperazin-1-yl] -propenone), or their pharmacologically acceptable salt, for the prevention and / Or treatment of functional pathological conditions of Pelvic floor - perineal, and especially Bladder pain syndrome -------------------------------------------------- -------------------------------------------------- - This invention involves the use of PAR1 antagonists, in particular. Warapasar type (vorapaxar), atopaxar and 3- (2- chloro-phenyl) -1- (4- (4- fluoro-benzyl) - piperacin. -1-il) - propenone (3- (2-chloro-phenyl) -1- (4- (4- fluoro-benzyl) -piperazn-1-yl] -propenone), or their pharmacologically acceptable salt. For the prevention and / or treatment of functional pathological conditions of the pelvic and perineal floor, and Especially more Bladder pain syndrome
Claims (1)
Publications (3)
| Publication Number | Publication Date |
|---|---|
| TH1601003560A TH1601003560A (en) | 2017-09-07 |
| TH167368A TH167368A (en) | 2017-09-07 |
| TH167368B true TH167368B (en) | 2017-09-07 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2601127T3 (en) | Pyrazole derivative and its use for medical purposes | |
| PH12016501457A1 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| EA201790528A1 (en) | DIHYDROPYRROLOPIRIDINOVYY INHIBITORS ROR-GAMMA | |
| PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| CL2015000578A1 (en) | Compound n- (2- (6-fluoro-1-h-indol-3-yl) ethyl) -3- (2,2,3,3-tetrafluoropropoxy) benzylamine or its salt, 5-ht6 receptor antagonist; pharmaceutical composition; Use in the treatment of Alzheimer's disease. | |
| TN2018000218A1 (en) | Indole carboxamides compounds useful as kinase inhibitors. | |
| MX2016016593A (en) | Novel aminoalkyl benzothiazepine derivative and use thereof. | |
| SG10201808053XA (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| MX2015016344A (en) | Imidazopyrrolidinone derivatives and their use in the treatment of disease. | |
| EA201990424A1 (en) | SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION | |
| EA201990428A1 (en) | SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION | |
| MX2015016421A (en) | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease. | |
| WO2016109217A3 (en) | Btk inhibitors | |
| PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
| EA201692298A1 (en) | DERIVATIVES OF CARBOXAMIDES | |
| CU20160166A7 (en) | COMPOUNDS DERIVED FROM N- (1,5-DIMETIL-3-OXO-2,3-DIHIDRO-1H-PIRAZOL-4-IL) -4-METHYL-5-ISOXAZOL-3-CARBOXAMIDE AS SELECTIVE INHIBITORS OF SMURF-1 | |
| AR094241A1 (en) | CICLESONIDE FOR THE TREATMENT OF RESPIRATORY ROAD DISEASE IN HORSES | |
| EA201692111A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES | |
| MX371102B (en) | New benzimidazole derivatives as antihistamine agents. | |
| CY1119522T1 (en) | (R) - PILINDOL AND THE PHARMACEUTICALALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | |
| RU2019104946A (en) | APPLICATION OF A DERIVATIVE CHROMON AS AN ANTAGONIST OF DOPHAMINE D3 RECEPTOR FOR THE TREATMENT OF DISORDERS OF THE AUTISTIC SPECTRUM | |
| EA201691796A1 (en) | N-SUBSTITUTED ASYMMETRIC UREA AND THEIR APPLICATION IN MEDICINE | |
| AU2014365665A1 (en) | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | |
| JP2016540799A5 (en) | ||
| TH167368B (en) | Use of PAR-1 antagonists for the prevention and / or treatment of the condition. Functional pathology of the pelvic-perineal floor. |